autologous anti-CD83 CAR T cells

A preparation of autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD83, with potential antineoplastic activity. Upon administration, autologous anti-CD83 CAR T cells recognize and kill CD83-expressing tumor cells. CD83 is expressed on acute myeloid leukemia (AML) blasts.